Citations

Clear

6055 citation(s) found for "Wu, Peter".

Utilization of thyroid nodule images in consultations: secondary evaluation of a pilot randomized study
Patel, Urja, Perneth, Sandra Algarin, Rocha, Andrea Ortiz , Barb, Diana, Acosta, Gonzalo, Srihari, Ashok, Dziegielewski, Peter, Kawkgi, Omar El, Castro, M Regina, Dean, Diana, Ryder, Mabel, Hargraves, Ian, Bylund, Carma L., Roy, Arkaprava , Zhang, Zhongyue , Montori, Víctor M. , Brito, Juan P., Ospina, Naykky M Singh, Barb, Diana , Dziegielewski, Peter T. , Kawkgi, Omar El , Castro, M Regina, Ryder, Mabel , Bylund, Carma L. , Brito, Juan P. , Ospina, Naykky Singh

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10842799/v1 Get It

Abstract Context. Thyroid nodule ultrasound findings are crucial in guiding management decisions for patients with thyroid nodules. However, the frequency with which ultrasound images are discussed and reviewed with patients during clinical visits is not well understood. Objective. To assess how often thyroid ultrasound images are shown and discussed with patients during consultations, and to identify predictors of image review during clinical visits. Design and setting. Secondary analysis of a multicenter pilot randomized clinical trial conducted at two academic medical centers in the United States. Participants. Adults undergoing evaluation for thyroid nodules. Intervention. Participants were randomized to receive either usual care or care enhanced with a conversation aid. Main Outcome Measures. The primary outcome was the frequency of thyroid nodule imaging review evaluated as a binary outcome. Secondary outcomes included evaluation of predictors of image discussion. Results. Eighty-five patients were evaluated. Most participants were women (80%), mean age (60 years, SD 16), and White (86%), undergoing new patient visits (84%). Thyroid nodule ultrasound images were reviewed with patients in 53% of visits (45/85), and in all cases, clinicians initiated the imaging discussion. Predictors of image review included type of consultation (new patient visit) (OR 10.6, 95% CI: 1.79, 62.3). Age, sex, study arm, thyroid nodule size or cancer risk and plan of care (e.g., completing a biopsy) were not statistically associated with review of clinical images. Conclusions. Review of thyroid ultrasound images during clinical visits is relatively common, with consultation type serving as significant predictor.
Normothermic Machine Perfusion, Patient-Centered Recovery, and Graft Survival After Donation-After-Circulatory-Death Liver Transplantation
Frasco, Peter E. , Mathur, Amit K, Zhang, Nan , Brennan, Bayley, Jadlowiec, Caroline, Milam, Adam J, Nguyen, Michelle K, Fah, Megan, Patel, Bhavesh M, Bettini, Layne M, Dholakia, Ruchita, Borah, Bijan, Barnhill, Michele , Aqel, Bashar, Jadlowiec, Caroline C. , Bettini, Layne M., Borah, Bijan J. , Barnhill, Michele

Mayo Clinic

Journal of the American College of Surgeons | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002226 | PMID 42770976 Get It

Background: Normothermic machine perfusion (NMP) may reduce preservation injury in donation-after-circulatory-death (DCD) liver transplantation, but its association with patient-centered recovery and longer-term graft survival remains uncertain. Study Design: We retrospectively analyzed 306 consecutive adult DCD liver transplant recipients at a single center from January 2019 through December 2022, comparing NMP (n=95) with static cold storage (SCS; n=211). The primary endpoint was days alive and out of hospital at 365 days (DAOH365). Quasi-Poisson regression evaluated factors associated with DAOH365, and Cox regression evaluated graft survival. Propensity-matched and calendar-year sensitivity analyses assessed measured confounding. Results: Median DAOH365 was 357.0 (352.0, 360.0) days with NMP versus 353.0 (336.0, 359.0) with SCS (p<0.001), but preservation strategy was not independently associated with DAOH365 (adjusted rate ratio 1.02; p=0.331). NMP recipients had less early allograft dysfunction (35.8% vs 59.7%; p<0.001), ischemic cholangiopathy (4.2% vs 23.7%; p<0.001), and retransplantation within 2 years (0.0% vs 6.6%; p=0.007). Two-year patient survival did not differ significantly. NMP was associated with improved twoF-year graft survival (HR 2.9, 95% CI 1.23–6.87; p=0.015), an association maintained in propensity-matched and calendar-year sensitivity analyses. Adjusted total 1-year costs did not differ (p=0.512). Conclusions: In this single-center DCD cohort, NMP was associated with superior 2-year graft survival but not independently with DAOH365. These hypothesis-generating findings support multicenter prospective evaluation of NMP using both graft survival and patient-centered recovery endpoints.
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer
Henstridge, Aylin Z. , Azorsa, Peter, Arya, Nandini , Elhossiny, Ahmed M. , Kadiyala, Padma , Goldwasser, Molly , Branch, Georgina , Sahai, Vaibhav , Peterson, Nicole , Machicado, Jorge D. , Kwon, Richard S. , Schulman, Allison R. , Wamsteker, Erik‐Jan , Philips, George, Menees, Stacy B. , Xia, Jonathan Y. , Hogenson, Tara L. , Rao, Arvind , Shi, Jiaqi , Frankel, Timothy L. , Bednar, Filip , Magliano, Marina Pasca di , Lyssiotis, Costas A. , Truty, Mark J. , Fernández-Zapico, Martín E. , Carpenter, Eileen S. , Azorsa, Peter A , Philips, George M , Pasca di Magliano, Marina , Lyssiotis, Costas A , Sahai, Vaibhav

Mayo Clinic

Cancer Research | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/0008-5472.can-26-0823 | PMID 42765602 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). Cytotoxic combination chemotherapy treatments are the mainstay of PDAC therapy, but patients rapidly develop chemoresistance, highlighting the need to elucidate how chemotherapy alters the TME and whether these changes drive chemoresistance. Here, we examined matched pre- and post-treatment tissue specimens using single-cell RNA-sequencing and found near-universal enrichment after treatment of axonal guidance genes in cancer-associated fibroblasts (CAFs). These neural CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrent lesions had the highest prevalence of neural CAFs versus primary tumors and untreated metastases. Neural CAFs showed elevated non-canonical WNT mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Additionally, in vitro studies revealed enrichment of axonal guidance genes in patient-derived CAF lines upon exposure to chemotherapy or tumor cells. Altogether, these findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising therapeutic target for this disease.
From Technical Performance to Clinical Readiness: A Phase-Based Framework for Evidence Standards in Clinical Artificial Intelligence
Nenadic, Ivan , Loring, Zak , Noseworthy, Peter A. , Ahmad, Faraz S. , Vasconcelos, Luiz , Fudim, Marat , Murthy, Venkatesh L. , Vasconcelos, Luiz , Noseworthy, Peter A , Ahmad, Faraz , Nenadic, Ivan

Mayo Clinic

NEJM AI | September 17, 2026 | Volume: 3 | Issue: 10 | Pages: No page available

10.1056/aip2600684 | PMID 42932701 Get It

TNFRSF17 (B Cell Maturation Antigen, BCMA) alterations and downstream compensatory pathway activation following BCMA-directed CAR T-cell and bispecific T-cell engagers in multiple myeloma
Dasari, Surendra , Zanwar, Saurabh , Khot, Amit , Dingli, David , Binder, Moritz , Kourelis, Taxiarchis , Gonsalves, Wilson I. , Dispenzieri, Angela , Warsame, Rahma, Cook, Joselle , Buadi, Francis K. , Jevremović, Dragan , Gertz, Morie A. , Rajkumar, S. Vincent , Kapoor, Prashant , Lin, Yi , Kumar, Shaji , Gonsalves, Wilson , Dingli, David , Dasari, Surendra , Khot, Amit , Rees, Matthew J. , Warsame, Rahma

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10945994/v1 Get It

Abstract BCMA-directed CAR T-cell and T-cell engager (TCE) therapies produce high response rates in relapsed multiple myeloma, yet most patients progress. Prior work identified TNFRSF17 alterations mediating antigen escape in up to 43% of TCE progressions. To evaluate the generalizability of these findings and examine antigen-loss-independent resistance, we performed whole-exome sequencing on 32 paired pre- and post-treatment progression bone marrow samples from 15 patients (5 CAR T, 10 TCE); two patients received both agents. TNFRSF17 alterations were infrequent and restricted to TCE recipients (one concurrent frameshift and missense mutation; two heterozygous copy-number losses); no biallelic loss or CAR T-associated events were observed. In contrast, deleterious/loss-of-function variants in NF-κB, PI3K-AKT-mTOR, and MAPK/ERK pathways were universal in pre-treatment samples and acquired or clonally enriched in 80% of patients at progression. Acquired events included loss-of-function alterations in CYLD , activating mutations in KRAS , NRAS and BRAF , and acquired TP53 mutations. In this series, antigen escape via TNFRSF17 /BCMA alteration was uncommon. Instead, pre-existing, acquired and clonally enriched pathogenic variants in NF-κB, PI3K-AKT-mTOR and MAPK cascades, together with TP53 mutation, emerged as a frequent finding. These alterations suggest that deregulation of BCMA-downstream survival signaling, enhanced proliferative fitness, and elevation of apoptotic threshold constitute antigen-loss-independent mechanisms of resistance.
The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank
Attaway, Amy , Serban, Karina, Dutta, Shovan, Hatipoğlu, Umur, Zein, Joe, Bazeley, Peter, Kyriakidou, Maria, Ruvuna, L. , Wade, R Chad, Bon, Jessica, Wells, J Michael, Ortega, Victor, Stoller, James K, Bowler, Russell, Attaway, Amy H , Serban, Karina A. , Dutta, Shovan , Hatipoğlu, Umur , Zein, Joe , Bazeley, Peter , Kyriakidou, M, Dawson, Jennifer E. , Tejwani, Vickram , Wells, J. Michael , Stoller, James K.

Mayo Clinic

No container title available | September 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.12.26362905 | PMID 42779858 Get It

Abstract Background Sarcopenia is common in chronic obstructive pulmonary disease (COPD) and contributes to adverse outcomes. Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause of COPD, but its impact on skeletal muscle remains to be determined. Methods We performed a retrospective analysis of 487,207 participants in the UK Biobank with available SERPINA1 genotyping. Associations between AAT genotypes and measures of skeletal muscle mass were determined using multivariable linear and logistic regression models. Models adjusted for age, sex, smoking status, genetic principal components, lung function (FEV₁% predicted), and liver fibrosis risk (FIB-4). We determined that the Z-allele was associated with sarcopenia and mortality using regression models and mediation analysis. Results Compared with PI*MM individuals, carriers of the Z allele (PI*MZ, PI*SZ, PI*ZZ) demonstrated significantly lower fat free mass index (FFMI) and appendicular skeletal muscle index (ASMI), as well as higher odds of sarcopenia by binary definition. Associations persisted after adjustment for lung and liver function. A dose-dependent relationship was observed, with the greatest reductions in muscle mass and highest sarcopenia associated with PI*ZZ individuals (adjusted OR for FFMI-defined sarcopenia 2.02, 95% CI 1.16-3.32). Each additional Z allele was associated with increased mortality risk (adjusted OR 1.09, 95% CI 1.02-1.16), with sarcopenia mediating a modest proportion (∼2.6%) of this association. Conclusions. The SERPINA1 Z allele is associated with reduced muscle mass and increased risk for sarcopenia independent of lung and liver disease. Our findings expand the phenotypic spectrum of AATD-related diseases to include skeletal muscle as a modifiable target for intervention.
Evidence for a tubular basement membrane–cilia connection in autosomal dominant polycystic kidney disease pathogenesis
Sussman, Caroline R. , Harris, Peter, Harris, Peter C.

Mayo Clinic

Journal of Clinical Investigation | September 14, 2026 | Volume: 136 | Issue: 18 | Pages: No page available

10.1172/jci210031 | PMID 42741939 Get It

Autosomal dominant polycystic kidney disease (ADPKD), mainly driven by pathogenic variants in PKD1 and PKD2 , is the most common inherited cause of kidney failure. Details of ADPKD pathogenesis are incompletely resolved, but primary cilia are an integral component. There is also evidence for changes to the tubular basement membrane (TBM) in early disease. In this issue of the JCI , Mazloum and colleagues link cilia-dependent, PKD1-mediated regulation of the TBM to ADPKD pathogenesis. Using in vivo, ex vivo, tubule-on-chip, and cellular models of ADPKD, they connect cilia-dependent tubule dilation and TBM thinning to early-stage cystogenesis. Moreover, they identify a cilia-dependent TBM remodeling expression signature in affected tubules and suggest that PC1 loss compromises TBM stiffness. By integrating roles for cilia at the apical membrane and extracellular matrix at the basolateral membrane in cystogenesis, this work highlights the TBM as an additional area for investigation of therapeutic and biomarker discovery in ADPKD.
CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease
Cao, Yingshu , Sun, Xiaobo , Huang, Yan , Ji, Biyun , Chen, Renee , Li, Yuan , Liang, Yan , Aghevli, Ariana, Patel, Vishal , Harris, Peter C. , Ling, Kun , Hu, Jinghua , Chen, Chuan , Ji, Biyun , Chen, Renee , Liang, Yan , Yang, Nicole, Patel, Vishal , Harris, Peter C , Ling, Kun , He, Kai , Chen, Chuan , Yang, Nicole, He, Kai

Mayo Clinic

Journal of the American Society of Nephrology | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001269 | PMID 42735034 Get It

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only FDA-approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a cilia base-localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacy of early- and late-stage intervention were assessed in F1(129/B6) Pkd1 R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study endpoints. Results: CDK6 was prominently upregulated in cyst-lining cells in human and murine PKD kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in females and reversed cyst progression in males. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions: Abemaciclib has greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition–mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Choudhury, Atish D. , Zhong, Caiwei , Xie, Wanling , Kochupurakkal, Bose , Wu, Peter I-Fan , Riaz, Irbaz Bin , Liu, Ruolin , Yang, David D. , Folefac, Edmund , Lee, Daniel , McKay, Rana R. , Pace, Amanda F. , Adalsteinsson, Viktor A. , Kunos, Charles A., Gore, Steven D. , Das, Biswajit , Taplin, Mary‐Ellen , Kochupurakkal, Bose S , Parikh, Mamta , Einstein, David J , Kessler, Elizabeth , Mayer, Tina , McKay, Rana R , Pace, Amanda , Mouw, Kent W , Chen, Li , Adalsteinsson, Viktor A , Van Allen, Eliezer M , Kunos, Charles , Gore, Steven D , Das, Biswasjit , D'Andrea, Alan , Taplin, Mary-Ellen , Shapiro, Geoffrey I , Choudhury, Atish D , Riaz, Irbaz B , Xie, Wanling , Wu, Peter I-Fan , Mouw, Kent W. , D’Andrea, Alan D. , Shapiro, Geoffrey I.

Mayo Clinic

Cancer Research Communications | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0488 | PMID 42636061 Get It

Abstract Purpose: Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer. Patients and Methods: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive Arm A (docetaxel 60 mg/m2+carboplatin AUC4 day 1; or carboplatin AUC5 if not a docetaxel candidate) or Arm B (berzosertib 90 mg/m2 days 2,9+carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; ≥50% PSA decline or radiographic response). Results: Of 73 randomized patients, 65 received protocol treatment: 34 on Arm A (26 docetaxel+carboplatin; 8 carboplatin alone) and 31 on Arm B. Thirteen patients (38%) in Arm A and 20 (65%) in Arm B had ≥Grade 3 treatment-related adverse events (TrAEs). ORR was 15% in Arm A (5/34; 5/26[19%] with docetaxel+carboplatin) and 0% in Arm B (0/31). At interim analysis after 65 of planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM-deficiency or high levels of phoshpo-KAP1 detected in tissue was associated with clinical benefit across both arms of the trial. Conclusions: Berzosertib+carboplatin demonstrated lower ORR and more frequent ≥grade 3 TrAEs compared to docetaxel+carboplatin in this heavily pre-treated, biomarker-unselected population. NCT03517969